Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Perimeter Medical Imaging AI develops real-time optical coherence tomography imaging systems and artificial-intelligence tools for cancer surgery. The company’s Claire OCT+AI device has FDA premarket approval for intraoperative breast cancer margin assessment, while its S-Series OCT platform provides ultra-high-resolution cross-sectional visualization of excised tissue.
Company news commonly covers FDA regulatory milestones, product demonstrations, commercialization activity, clinical and technology updates, operating and financial results, investor conference presentations, and capital-structure actions such as private placements, warrants, and stock-option matters.
Perimeter Medical Imaging AI (OTCQX:PYNKF, TSXV:PINK) announced that CEO Adrian Mendes will present a company update at the Planet MicroCap Showcase in Las Vegas on Wednesday, June 17, 2026, at 12:00 p.m. PDT (3:00 p.m. EDT).
A live and archived webcast of the presentation will be available on Perimeter's website, and investors can register for the event and request 1x1 meetings with management.
Perimeter (OTCQX:PYNKF) was selected for the INOVAIT Pilot Fund to advance AI for its FDA-approved intraoperative breast cancer imaging platform Claire™.
The project, partnered with the University of Toronto, may receive up to about $148,000 from INOVAIT plus a $100,000 Mitacs award.
Perimeter (OTCQX:PYNKF) reported Q1 2026 revenue of approximately $385,000, all from recurring sources, versus $550,000 in Q1 2025, which included $230,000 of one-time capital equipment sales.
Operating expenses fell 30% to $3.2 million, net loss improved 31% to $3.0 million, and cash used in operations declined 41% to $2.2 million. Perimeter received FDA PMA approval for its AI-enabled Claire OCT device, secured its first two commercial placements, cancelled 14.5 million warrants, repriced employee options, and raised roughly $7.5 million in gross proceeds through debentures and a unit offering, with up to $3.0 million more debentures expected.
Perimeter Medical Imaging AI (OTCQX:PYNKF) will release its first quarter 2026 financial and operating results after market close on Thursday, May 28, 2026. Management will host a webcast and conference call at 5:00 p.m. Eastern Time to discuss results and provide a corporate update.
The call will be accessible via dial-in numbers for North America and international participants and will also be broadcast live and archived on the company’s website for later listening.
Perimeter (OTCQX: PYNKF) unveiled Claire™, an OCT+AI imaging system for intraoperative breast cancer margin assessment, at ASBrS 2026 (April 29–May 3) with live demos at Booth #325.
Claire received FDA PMA in March 2026 as the first AI-enabled U.S. device for this use, offers 10x higher resolution than X-ray/ultrasound at a 2mm imaging depth, and was trained on a library of over 2 million breast OCT images; commercial launch is pending.
Perimeter Medical Imaging AI (OTCQX: PYNKF) will present an update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026 at 10:00 a.m. ET at the Metro Toronto Convention Centre.
The presentation will be broadcast live and later archived in the company's Investors section under "News/Events."
Perimeter Medical Imaging AI (OTCQX: PYNKF) reported preliminary unaudited Q4 and full-year 2025 results showing record revenue and improved operating performance. FY2025 revenue was approximately $2.3M (up 172% YoY); Q4-2025 revenue was approximately $711K (up 143% YoY). The company received FDA PMA approval for Claire in March 2026 and expects a U.S. commercial launch in Q2-2026. Operating expenses and cash used in operations both improved year-over-year; cash on hand was approximately $2.5M as of December 31, 2025.
Perimeter Medical Imaging AI (OTCQX: PYNKF) will report fourth quarter and full year 2025 results after market close on March 31, 2026 and will host a webcast and conference call at 5:00 pm ET.
The company also entered a warrant cancellation agreement with Social Capital, surrendering 14,466,667 warrants for no consideration, reducing Social Capital's partially‑diluted stake from 30% to 22.3% (non‑diluted stake remains 22.2%).
Perimeter Medical Imaging AI (OTCQX: PYNKF) received FDA premarket approval (PMA) for Claire, the first FDA‑approved AI‑enabled intraoperative imaging device for breast cancer margin assessment. Claire demonstrated 88.1% margin accuracy and a statistically significant reduction in residual cancer; a nationwide launch begins in the coming weeks.
Claire combines patented wide‑field OCT with an AI trained on >2 million OCT images, offers ~10x higher resolution at 2mm depth, has Breakthrough Device designation, and targets an estimated 300,000 annual U.S. breast‑conserving surgeries.
Perimeter Medical Imaging AI (OTCQX: PYNKF) plans to cancel up to 2,175,619 previously issued stock options and re-grant the same number as replacement options exercisable at C$0.30 per share.
The Replacement Options vest in three schedules beginning Jan 1, 2026, retain the Original Options' expiry dates, exclude directors and officers, and are subject to approval as a re-pricing by the TSX Venture Exchange.